Ursodeoxycholic acid reduces the risk of developing colorectal cancer in patients with ulcerative colitis and sclerosing cholangitis

2003 ◽  
Vol 124 (4) ◽  
pp. 873
Keyword(s):  
Colorectal Cancer ◽  
Ulcerative Colitis ◽  
Ursodeoxycholic Acid ◽  
Sclerosing Cholangitis

scholarly journals Is there an excess risk for colorectal cancer in patients with ulcerative colitis and concomitant primary sclerosing cholangitis? A population based study

Gut ◽  
1997 ◽  
Vol 41 (4) ◽  
pp. 522-525 ◽  
Author(s):  
D Kornfeld ◽  
A Ekbom ◽  
T Ihre
Keyword(s):  
Colorectal Cancer ◽  
Ulcerative Colitis ◽  
Primary Sclerosing Cholangitis ◽  
Sclerosing Cholangitis ◽  
Cumulative Risk ◽  
Population Based ◽  
Colorectal Cancers ◽  
Population Based Study ◽  
Increased Risk ◽  
Swedish Cancer Registry

Background—Patients with ulcerative colitis have an increased risk of colorectal cancer. Duration, age, and extent of the disease at diagnosis are the only established risk factors. Patients with ulcerative colitis and concomitant primary sclerosing cholangitis (PSC) have been reported to have a higher frequency of colonic DNA aneuploidy and/or dysplasia than expected, findings indicating an increased risk of colorectal cancer compared with other patients with ulcerative colitis.Methods—A population based cohort consisting of 125 patients with a verified diagnosis of PSC was followed up by linkage to the Swedish Cancer Registry for the occurrence of colorectal cancer.Results—There were 12 colorectal cancers. Six cancers were diagnosed prior to the diagnosis of PSC. Among the 104 patients with an intact colon at the time of the diagnosis of PSC there was a cumulative risk for colorectal cancer of 16% after 10 years. Among the 58 patients with a diagnosis of ulcerative colitis and colorectal cancer prior to the diagnosis of PSC, there were five colorectal cancers corresponding to a cumulative risk of 25% after 10 years.Conclusions—Patients with ulcerative colitis and concomitant PSC seem to constitute a subgroup with a high risk for colorectal cancer.

938 PRIMARY SCLEROSING CHOLANGITIS IS A RISK FACTOR FOR COLORECTAL CANCER IN YOUNG ULCERATIVE COLITIS PATIENTS

2012 ◽  
Vol 56 ◽  
pp. S366
Author(s):  
K. Boonstra ◽  
B.D. van Rhijn ◽  
E.P.M. Karregat ◽  
P.J. Kingma ◽  
A.H.J. Naber ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Ulcerative Colitis ◽  
Risk Factor ◽  
Primary Sclerosing Cholangitis ◽  
Sclerosing Cholangitis

scholarly journals DIAGNOSTIC AND MANAGEMENT APPROACH TO POUCHITIS IN INFLAMMATORY BOWEL DISEASE

2020 ◽  
Vol 57 (1) ◽  
pp. 100-106 ◽  
Author(s):  
Rocío SEDANO ◽  
Paulina NUÑEZ ◽  
Rodrigo QUERA
Keyword(s):  
Colorectal Cancer ◽  
Risk Factors ◽  
Ulcerative Colitis ◽  
Inflammatory Bowel Disease ◽  
Sclerosing Cholangitis ◽  
Biological Therapy ◽  
Response To Therapy ◽  
Management Approach ◽  
Total Proctocolectomy ◽  
Inflammatory Bowel

ABSTRACT In patients with ulcerative colitis refractory to medical therapy, total proctocolectomy and posterior ileal-anal pouch anastomosis is the standard surgical therapy. One of the possible complications is pouchitis. Depending on the duration of the symptoms, it can be classified as acute, recurrent, or chronic. The latter, according to the response to therapy, can be defined as antibiotic-dependent or refractory. The treatment of pouchitis is based on the use of antibiotics and probiotics. Thiopurine and biological therapy have been suggested in patients with refractory pouchitis. Special care should be taken in the endoscopic surveillance of these patients, especially if they present risk factors such as dysplasia or previous colorectal cancer, primary sclerosing cholangitis or ulcerative colitis for more than 10 years.

scholarly journals Tissue-dependent transcriptional and bacterial associations in primary sclerosing cholangitis-associated inflammatory bowel disease

2021 ◽  
Vol 6 ◽  
pp. 199
Author(s):  
Nicholas E. Ilott ◽  
Mastura Neyazi ◽  
Carolina V. Arancibia-Cárcamo ◽  
Fiona Powrie ◽  
Alessandra Geremia
Keyword(s):  
Colorectal Cancer ◽  
Ulcerative Colitis ◽  
Inflammatory Bowel Disease ◽  
Cancer Risk ◽  
Sclerosing Cholangitis ◽  
Gamma Glutamyl Transferase ◽  
Transcriptional Alterations ◽  
Inflammatory Bowel ◽  
Bacterial Associations ◽  
Glutamyl Transferase

Background: Primary sclerosing cholangitis (PSC) is a disease of the bile duct and liver. However, patients frequently have co-morbidities including inflammatory bowel disease (IBD) and colorectal cancer. Colorectal cancer risk in patients with PSC-associated ulcerative colitis (PSC/UC) is elevated relative to patients with ulcerative colitis (UC) alone, reasons for which remain obscure. Further, clinical and immunological features, and involved intestinal sites differ between PSC/UC and UC. Understanding the molecular and microbial basis for differences in cancer risk between these two patient groups and how these differ across intestinal sites is important for the development of therapies to prevent colorectal cancer development in at-risk individuals.   Methods: We employed ribonucleic acid sequencing (RNA-seq) analysis of biopsy samples across three intestinal tissue locations (ileum, caecum and rectum) in patients with PSC/UC (n = 8), UC (n = 10) and healthy controls (n = 12) to determine tissue-dependent transcriptional alterations in PSC/UC. We also performed 16S ribosomal RNA (rRNA) amplicon sequencing to determine bacterial associations with PSC/UC and host-microbiome associations. Results: Tissue-defining transcriptional signatures revealed that the ileum was enriched for genes involved in lipid and drug metabolism, the caecum for activated immune cells and the rectum for enteric neurogenesis. Transcriptional alterations relative to healthy control samples were largely shared between patients with PSC/UC or UC although were distinct across tissue locations. Nevertheless, we observed reduced expression of gamma-glutamyl transferase 1 (GGT1) specifically in the ileum and caecum of patients with PSC/UC. Analysis of the bacterial component of the microbiome revealed high inter-individual variability of microbiome composition and little evidence for tissue-dependency. We observed a reduction in Parabacteroides relative abundance in the rectum of patients with PSC/UC. Conclusions: The role of gamma-glutamyl transferase in maintaining the redox environment through the glutathione salvage pathway makes our observed alterations a potential pathway to PSC-associated colorectal cancer.

Sign in / Sign up

Export Citation Format

Share Document